相似文献
1
Correction to Supporting Information for Tili et al., -targeted IcosL controls tumor rejection.
Proc Natl Acad Sci U S A. 2024 Sep 17;121(38):e2416854121. doi: 10.1073/pnas.2416854121. Epub 2024 Sep 9.
2
-targeted IcosL controls tumor rejection.
Proc Natl Acad Sci U S A. 2024 Jul 16;121(29):e2408649121. doi: 10.1073/pnas.2408649121. Epub 2024 Jul 9.
3
Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
Blood. 2024 Feb 1;143(5):429-443. doi: 10.1182/blood.2023021346.
4
Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro.
Eur J Immunol. 2005 Jun;35(6):1712-21. doi: 10.1002/eji.200425727.
5
Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Biomed Pharmacother. 2019 Oct;118:109333. doi: 10.1016/j.biopha.2019.109333. Epub 2019 Aug 22.
6
Evaluation of tyrosinase inhibitory activity and mechanism of Leucrocin I and its modified peptides.
J Biosci Bioeng. 2020 Sep;130(3):239-246. doi: 10.1016/j.jbiosc.2020.04.002. Epub 2020 May 7.
7
Therapeutic Index for Local Infections score validity: a retrospective European analysis.
J Wound Care. 2020 Dec 2;29(12):726-734. doi: 10.12968/jowc.2020.29.12.726.
8
Evaluation of TILI-2 as an Anti-Tyrosinase, Anti-Oxidative Agent and Its Role in Preventing Melanogenesis Using a Proteomics Approach.
Molecules. 2022 May 18;27(10):3228. doi: 10.3390/molecules27103228.
9
Enhanced CD40 and ICOSL expression on dendritic cells surface improve anti-tumor immune responses; effectiveness of mRNA/chitosan nanoparticles.
Immunopharmacol Immunotoxicol. 2018 Oct;40(5):375-386. doi: 10.1080/08923973.2018.1510959. Epub 2018 Sep 28.
10
T helper 22 cells from Han Chinese patients with atopic dermatitis exhibit high expression of inducible T-cell costimulator.
Br J Dermatol. 2020 Mar;182(3):648-657. doi: 10.1111/bjd.18040. Epub 2019 Aug 19.
引用本文的文献
1
impairs ICOSL and MHC-I expression in DLBCL lymphomas.
Proc Natl Acad Sci U S A. 2025 Apr 22;122(16):e2422615122. doi: 10.1073/pnas.2422615122. Epub 2025 Apr 18.
Zotero 插件